Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200
Clinical trial NCT00455910 · COMPLETED
Trial details
- NCT number
- NCT00455910
- Sponsor
- Groupe Francophone des Myelodysplasies
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2003-01-01
- Enrollment
- 112
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.